Dren Bio has closed an oversubscribed $350 million private financing to advance its lead antibody therapy dibotatug toward regulatory submission and commercialization while expanding its broader oncology and autoimmune pipeline. The financing was co-led by Juvia Group and Lightspeed Venture Partners. New investors included Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed.
Existing investors participating in the round included 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, and ArrowMark Partners.
Dibotatug, also known as DR-01, is an investigational monoclonal antibody targeting CD94 and is designed to selectively deplete pathogenic cytotoxic cells while preserving the broader immune system.
The drug is in advanced clinical development for cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, two rare blood cancers with significant unmet medical need and no approved therapies.
Dren Bio said more than 300 patients have been dosed in Phase 1/2 studies of dibotatug.
The company is also studying the drug in aplastic anemia, other bone marrow failure syndromes, and autoimmune diseases.
Proceeds will support late-stage trials, regulatory work, preparations for a commercial launch, and additional indications.
The financing will also accelerate programs using Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform.
The platform develops multispecific antibodies designed to trigger controlled depletion of disease-causing cells and other targets through myeloid cells.
Its first platform program was acquired by Sanofi in May 2025, while a second candidate is being evaluated for solid tumors.
KEY QUOTES:
“Today’s financing, supported by an exceptional group of new and existing investors who share our mission is a proud moment for the team, and positions us to accelerate the development of novel therapies for a range of diseases.”
Nenad Tomasevic, Ph.D., CEO And Founder Of Dren Bio
“We believe dibotatug has the potential to dramatically change the treatment paradigm in multiple hematologic and autoimmune diseases with substantial unmet need.”
Sujal Shah, Co-Founder And Managing Director At Juvia Group

